Alumis Inc. (ALMS) Stock Price & Analysis
Alumis Inc. (ALMS) fell 2.29% to USD 11.1 as of September 8, 2026 at 05:43 UTC, according to Nexqual real-time market data.
ALMS last closed at USD 11.36; the session ranged USD 11.01–11.6 on volume of 3,078,140 shares. Market capitalization is $1.44B, with a 52-week range of USD 3.76–31.35 (NMS). Source: Nexqual, September 8, 2026 at 05:43 UTC.
Key Statistics (as of September 8, 2026 at 05:43 UTC)
| Price | USD 11.1 |
|---|---|
| Change | ▼ 2.29% (down) |
| Previous Close | USD 11.36 |
| Open | USD 11.23 |
| Day Range | USD 11.01 – 11.6 |
| 52-Week Range | USD 3.76 – 31.35 |
| Volume | 3,078,140 shares |
| Market Cap | $1.44B |
| Exchange | NMS |
Technical Analysis (ALMS)
Nexqual's technical model rates ALMS "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 21.28 (oversold) |
| vs SMA50 | Below (USD 25.32) |
| MACD | -3.71 (negative) |
Analyst Ratings (ALMS)
Wall Street analysts rate ALMS "Strong Buy" based on 8 analysts, with a mean price target of USD 32.13 (range USD 15–46), per Nexqual as of September 8, 2026 at 05:43 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 32.13 |
| High Target | USD 46 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (ALMS)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.75 |
| Revenue Estimate | $1.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.79 vs est -0.71 ▼ miss |
| 2026-03-31 | USD -0.74 vs est -0.83 ▲ beat |
| 2025-12-31 | USD -0.25 vs est -0.98 ▲ beat |
| 2025-09-30 | USD -1.06 vs est -1 ▼ miss |
Source: Nexqual, September 8, 2026 at 05:43 UTC.
Financials & Fundamentals (ALMS)
| Total Revenue | $7.40M |
|---|---|
| Revenue Growth (YoY) | -37.70% |
| Gross Margin | +100.00% |
| Operating Margin | -6439.89% |
| Profit Margin | +0.00% |
| ROE | -93.65% |
| Debt / Equity | 8.06 |
| Current Ratio | 6.74 |
| Total Cash | $502.29M |
| Total Debt | $36.43M |
| Free Cash Flow | $-208.64M |
Source: Nexqual, September 8, 2026 at 05:43 UTC.
Financial Health Score (ALMS)
Nexqual rates Alumis Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 05:43 UTC.
| Growth | Critical — Revenue -38% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $502M cash vs $36M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$209M, burning cash |
| Efficiency | Critical — ROE -94%, ROA -45.3% |
Ownership (ALMS)
| Insider Ownership | +0.52% |
|---|---|
| Institutional Ownership | +93.24% |
| Shares Outstanding | 129.44M |
| Float | 104.39M |
| Short % of Float | +7.54% |
Source: Nexqual, September 8, 2026 at 05:43 UTC.
Leadership (ALMS)
Alumis Inc. is led by Martin Babler (age 60), President, CEO & Chairman, per Nexqual as of September 8, 2026 at 05:43 UTC.
| President, CEO & Chairman | Martin Babler (age 60) |
|---|---|
| Chief Scientific Officer | David M. Goldstein (age 59) |
| Chief Financial Officer | John R. Schroer C.F.A. (age 60) |
Major Backers & Investors (ALMS)
Notable institutional backers of Alumis Inc. include Ayurmaya Capital Management Company, LP, Foresite Capital Management V, LLC, FMR, LLC, according to Nexqual as of September 8, 2026 at 05:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ayurmaya Capital Management Company, LP | 11.7% |
| Foresite Capital Management V, LLC | 7.84% |
| FMR, LLC | 5.23% |
| Deep Track Capital, Lp | 4.9% |
| Samsara BioCapital, LLC | 4.9% |
| Price (T.Rowe) Associates Inc | 4.02% |
| venBio Partners LLC | 3.5% |
| Fidelity | 3.42% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.91% |
| Vanguard Group | 6.44% |
Source: Nexqual, September 8, 2026 at 05:43 UTC.
From Alumis Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
- The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
- It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBX | MBX Biosciences, Inc. | USD 61.72 | ▲ 1.36% |
| ABVX | Abivax SA | USD 114.79 | ▲ 3.34% |
| MLYS | Mineralys Therapeutics, Inc. | USD 28.21 | ▼ 2.86% |
| ERAS | Erasca, Inc. | USD 16.19 | ▼ 1.1% |
| ARTV | Artiva Biotherapeutics, Inc. | USD 11.19 | ▼ 1.06% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:43 UTC. This page is informational and not investment advice.